The company will highlight new high-potency manufacturing capabilities, novel botanically sourced APIs and a major strategic collaboration with TCG GreenChem to develop next-generation antibody-drug conjugates (ADCs).
At its upgraded Settala (Milan) facility, Indena has expanded its GMP synthetic plant and kilolab units to handle highly potent molecules (up to OEB5) safely and efficiently.
Key installations include a new filter dryer, large-scale reactors (up to 10,000 L), and a 250 L hydrogenator for advanced chemical synthesis.
A new 400 m² R&D lab with high-containment hoods and glove boxes supports research on HPAPIs (Highly Potent Active Pharmaceutical Ingredients).
The company also continues investing in biotransformation and fermentation technologies to supply toxins for ADC payloads, strengthening its fully integrated production model.
Indena will also showcase sustainable and traceable botanical APIs:
- squalene is a plant-derived alternative from Amaranthus species, used as an adjuvant in vaccines and replacing animal sources
- cytisine is an anti-smoking agent obtained from Laburnum anagyroides Medik, cultivated under strict traceability standards.
Additionally, Indena’s proprietary semi-synthetic process for taxanes (paclitaxel, docetaxel, cabazitaxel) ensures secure and ecofriendly production for oncology drugs.
A highlight of CPHI 2025 will be the Indena–TCG GreenChem partnership, combining Indena’s expertise in HPAPI payloads with TCG’s green chemistry innovations to advance ADC process development.
Joint presentations by Pietro Allegrini (Indena) and Chris Senanayake (TCG GreenChem) will introduce this collaboration on 28 October, followed by a sustainability focused panel featuring Francesca De Rensis on 30 October.
With more than a century of botanical research, four production sites and operations in more than 80 countries, Indena reinforces its position as a leader in sustainable CDMO services and natural API innovation.
Visit Indena at Booth 5.0C102, Messe Frankfurt, 28–30 October 2025.